Amendments to the Specification

Please amend the Specification as indicated below.

Please replace paragraph [0019], on page 6, lines 15-16 as follows:

[0019] A preferred denatured laminin selective antagonist for use in the present invention is a peptide having the amino acid sequence NH_2-S-T-Q-N-A-S-L-L-S-L-T-V-C-COOH (SEQ ID NO 1).

Please replace paragraph [0020], on page 6, lines 17-19 as follows:

[0020] Another preferred denatured laminin selective antagonist for use in the present invention is a peptide having the amino acid sequence NH_2-K-G-G-C-S-T-Q-N-A-Q-L-L-S-L-I-V-G-K-A-COOH (STQ-peptide) (SEQ ID NO 2).

Please replace paragraph [0021], on page 6, lines 20-22 as follows:

[0021] Another preferred denatured laminin selective antagonist for use in the present invention is a peptide having the amino acid sequence NH_2-K-G-G-S-T-Q-N-A-Q-L-L-S-L-I-V-G-K-A-COOH (STQ-peptide-S) (SEQ ID NO 3).

Please replace paragraph [0052], on page 13, lines 14-23 as follows:

[0052] One preferred denatured laminin selective antagonist for use in the present invention is STQ-peptide. STQ-peptide binds to denatured laminin with high specificity. The amino acid sequence of STQ peptide is NH_2-K-G-G-C-S-T-Q-N-A-Q-L-L-S-L-I-V-G-K-A-COOH (SEQ ID NO 2). The STQ-peptide binds to regions within denatured laminin and inhibits cellular interactions with denatured laminin. Adhesive cellular interactions with functional epitopes within the extracellular matrix have a role in regulating angiogenesis, tumor growth and metastasis in vivo. (Xu, J., et al., J. Cell Biol. 2001; 154:1069-1079; Hangia, et al., Am. J. Pathol. 2002; 161:1429-1437). STQ-peptide has been shown to potently block angiogenesis (Example 5 below) and tumor growth and metastasis (Example 6 below) in vivo.

Please replace paragraph [0053], on page 14, lines 1-4 as follows:

[0053] Another preferred denatured laminin selective antagonist for use in the present invention is STQ-peptide-S. STQ-peptide-S binds with high specificity to denatured laminin and inhibits cellular interactions with denatured laminin. The amino acid sequence of STQ-peptide-S is NH_2-K-G-G-S-T-Q-N-A-Q-L-L-S-L-I-V-G-K-A-COOH (SEQ ID NO 3).

Please replace paragraph [0054], on page 14, lines 5-8 as follows:

[0054] A further preferred denatured laminin selective antagonist for use in the present invention has the amino acid sequence NH_2-S-T-Q-N-A-S-L-L-S-L-T-V-C-COOH (SEQ ID NO 1), which binds with high specificity to denatured laminin and inhibits cellular interactions with denatured laminin.

Please replace paragraph [0113], on page 30, lines 2-11 as follows:

[0113] The present invention contemplates therapeutic compositions useful for practicing the therapeutic methods of the present invention. Therapeutic compositions of the present invention contain a pharmaceutically acceptable carrier together with a denatured laminin selective antagonist as described herein, dissolved or dispersed therein as an active ingredient. In a preferred embodiment, the therapeutic denatured laminin selective antagonist composition is not immunogenic when administered to a mammal or human patient for therapeutic purposes. A preferred denatured laminin selective antagonist is STQ-peptide. Another preferred denatured laminin selective antagonist is STQ-peptide-S. Another preferred denatured laminin selective antagonist has the amino acid sequence NH_2-S-T-Q-N-A-S-L-L-S-L-T-V-C-COOH (SEQ ID NO 1).